Clinical trials
Hepatitis clinical trials
Below are recruiting hepatitis clinical trials, each written for real people, not researchers. We’re tracking 480 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT02863757Recruiting
Follow-up study for chronic hepatitis B with fatty liver
This study follows people who have chronic hepatitis B and also have fat buildup in the liver (nonalcoholic fatty liver disease). It’s looking at how these conditions behave over time and what may help, using information collected during follow-up visits.
Hong Kong, Hong KongAges Any age - NCT03097952Recruiting
Study of people with long-term hepatitis B in real life
This “real-life” study follows people with chronic hepatitis B to better understand their health over time. It may help researchers learn which factors affect outcomes in everyday care.
Changzhou, JiangsuAges Any age - NCT03686137Recruiting
Liver surgery database study for liver tumors
This study collects information from people having liver surgery for a non-cancerous tumor or for liver cancer (primary or cancer that spread to the liver). It doesn’t usually add treatment—your care is documented to help doctors learn and improve future decisions.
Marseille, Bouches Du RhoneAges 18 years+ - NCT04782557Recruiting
Ultrasound-guided blood sampling to track cancer DNA
This study uses an ultrasound-guided procedure to collect blood and check for cancer DNA (small bits of tumor material in the bloodstream). It aims to see whether this method can better track how gastric, pancreatic, or colorectal cancer responds to treatment.
Hong KongAges Any age - NCT03569826Recruiting
Study for primary biliary cholangitis and autoimmune hepatitis
This study is for people diagnosed with primary biliary cholangitis or autoimmune hepatitis. It aims to learn more about these autoimmune liver conditions and may help guide better care in the future.
Calgary, AlbertaAges 18 years+ - NCT05255978Recruiting
Follow-up study for hepatitis B with fatty liver
This observational study looks at people with chronic hepatitis B who also have fatty liver (non-alcoholic fatty liver disease). It follows how their liver health changes over time and may help doctors understand outcomes and risk factors.
Wuhan, HubeiAges 18 years+ - NCT05195450Recruiting
Tenofovir to stop liver disease in mild hepatitis B
This trial tests tenofovir alafenamide (a hepatitis B antiviral medicine) to see if it can prevent liver disease from getting worse in people with chronic hepatitis B who currently have stable (normal) liver blood tests and low virus levels. It may help lower the chance of developing serious liver complications over time.
New Delhi, National Capital Territory of DelhiAges 18–70 - NCT05335603Recruiting
Study of adults with liver conditions linked to fatty liver
This study looks at adults with different long-term liver conditions that are associated with fatty liver. It helps researchers better understand these diseases and factors linked to them.
HvidovreAges 18 years+ - NCT05392387Recruiting
Treatment and outcomes study for long-term hepatitis B
This trial looks at people with long-term hepatitis B infection and studies how treatment may affect health over time. It may help you understand whether your care improves outcomes for chronic hepatitis B.
Changsha, HunanAges 18–79 - NCT03308916Recruiting
Screening for liver scarring risk using noninvasive tests
This study checks people who are at higher risk for liver scarring by using noninvasive tests. If those tests suggest significant scarring, the study may consider further testing, but not everyone will need a biopsy.
OdenseAges 30–75 - NCT05661786Recruiting
Study outcomes for hepatitis B with “indeterminate” disease phase
This trial studies what happens to people with hepatitis B who have hepatitis B surface antigen for more than 6 months, are “HBeAg-negative,” and have certain blood and liver-scarring levels despite normal or near-normal liver inflammation. It may help doctors understand the best care for this specific group before clear treatment phases.
Changzhou, JiangsuAges 18 years+ - NCT05793203Recruiting
Tests noninvasive checks to spot liver transplant complications early
This study looks at how well noninvasive tests (tests that don’t require surgery or taking tissue) can detect complications after a liver transplant. It may help patients and teams find problems earlier using safer, easier monitoring.
RomeAges 18–75 - NCT05937178Recruiting
Real-World Study to Optimize Hepatitis B Tablet Treatment
This study looks at how to best use existing hepatitis B “nucleotide-analog” tablets in everyday care. It may help tailor when to start, and whether to continue or adjust treatment, based on your test results.
Hefei, AnhuiAges 18–80 - NCT05686785Recruiting
Test how reliable a liver scan is in chronic hepatitis
This study checks whether a “liver stiffness” scan (called transient elastography) gives consistent, dependable results in adults with long-term viral hepatitis. It may help improve how doctors monitor liver changes over time.
Helsingborg, Skåne CountyAges 18 years+ - NCT04446832Recruiting
Vaccine study for people waiting for liver transplant
This study tests a vaccine strategy for people who are being evaluated and waiting for a liver transplant. The goal is to see how well the immune system responds and how the results are interpreted before transplant.
LyonAges 18 years+ - NCT05557448RecruitingPhase 2
N-Acetylcysteine treatment for serious acetaminophen overdose
This Phase 2 trial studies whether TYNADOTE® can treat people who have taken a harmful acetaminophen (Tylenol) overdose while checking safety. It may be considered if your overdose is high enough to put you at risk for liver injury and you can follow the treatment and follow-up visits.
Taipei, Beitou DistrictAges 20 years+ - NCT06201065RecruitingPhase 3
Targeted therapy and immunotherapy for advanced liver cancer
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
Guangzhou, GuangdongAges 18–75 - NCT06210178Recruiting
New way to measure liver pressure without needles
This study tests a new, non-invasive method (using an MRI) to estimate pressure in the veins of the liver. If successful, it could replace the need for a catheter procedure for patients being evaluated for a liver transplant.
Leiden, South HollandAges 18–75 - NCT06244225RecruitingPhase 2
Triple therapy for advanced liver cancer (HAIC + sintilimab + donafenib)
This trial tests a combination of three treatments for advanced liver cancer that cannot be removed by surgery: a targeted oral drug (Donafenib), an immunotherapy (Sintilimab), and a type of chemotherapy given directly into the liver artery. The goal is to see if this triple therapy works better than current options for people who have not had any prior cancer treatment.
Wuhan, HubeiAges 18 years+ - NCT07867587Enrolling by invitation
Radiological treatment for blocked portal vein in children
This study tests a minimally invasive procedure to restore blood flow in children with a blocked portal vein (the major vein carrying blood from the intestines to the liver). It aims to reduce complications like bleeding from enlarged veins in the stomach or esophagus, an enlarged spleen, or fluid buildup in the belly.
CairoAges 2–17 - NCT04231565Recruiting
Testing antiviral medicines for hepatitis B with normal liver blood tests
This trial studies how well nucleoside (nucleoside-acid) type antiviral medicines control hepatitis B in people whose liver enzyme test (ALT) is currently normal. It may help those with active hepatitis B but no major liver inflammation on recent bloodwork.
Guangzhou, GuangdongAges 18–65 - NCT03811236Recruiting
Test cold exposure to activate body fat and reduce liver fat
This study tests whether controlled cold exposure can activate “brown fat” and affect liver fat buildup. It may help people with excess liver fat, measured on imaging, but it has several health and medication exclusions.
ViennaAges 18–50 - NCT06180590Recruiting
Vosevi for hepatitis C patients who didn't get better with past antiviral treatment
This trial tests if Vosevi (a combination of three antiviral drugs) can clear the hepatitis C virus in people who have already tried standard antiviral treatment but still have the virus. It also compares this to another treatment option.
Guangzhou, GuangdongAges 20–70 - NCT06323681Recruiting
Lower-dose interferon for chronic hepatitis B patients who've tried it before
This study tests a lower dose of pegylated interferon for people with chronic hepatitis B whose virus levels dropped significantly during a previous interferon treatment. It aims to see if a second round can further reduce or clear the virus.
Shanghai, Shanghai MunicipalityAges 18–65
Hear when a new Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatitis?
- Yes. Clin2 currently lists 480 recruiting hepatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.